Table 1.
Patient demographics and baseline characteristics.
| Patients (n = 55) | |
|---|---|
| Age (years), median (IQR) | 54 (46–62) |
| Sex, n (%) | |
| Male | 45 (81.8%) |
| Female | 10 (18.2%) |
| ECOG-PS, n (%) | |
| 0 | 47 (85.5%) |
| 1 | 8 (14.5%) |
| Child-Pugh, n (%) | |
| 5 | 24 (43.6%) |
| 6 | 31 (56.4%) |
| Hepatitis B infection, n (%) | |
| Yes | 27 (49.1%) |
| No | 28 (50.9%) |
| HBV-DNA copy, n (%) | |
| <2000 copy/mL | 31 (56.4%) |
| ≥2000 copy/mL | 19 (34.5%) |
| Unknown | 5 (9.1%) |
| AFP, n (%) | |
| <400 ng/mL | 23 (41.8%) |
| ≥400 ng/mL | 32 (58.2%) |
| PIVKA-II, n (%) | |
| <400 mAU/mL | 7 (12.7%) |
| ≥400 mAU/mL | 47 (85.5%) |
| Unknown | 1 (1.8%) |
| PVTT type, n (%) | 37 (67.3%) |
| I | 4 (7.3%) |
| II | 26 (47.3%) |
| III | 4 (7.3%) |
| IV | 3 (5.5%) |
| Extrahepatic metastasis, n (%) | |
| Yes | 10 (18.2%) |
| No | 45 (81.8%) |
| Extrahepatic metastasis location, n (%) | |
| Lung | 5 (9.1%) |
| Lymph node | 4 (7.3%) |
| Adrenal gland | 1 (1.8%) |
| Tumour number, n (%) | |
| Solitary | 32 (58.2%) |
| Multiple | 23 (41.8%) |
| Maximum tumour size (mm), mean ± SD | 101.7 ± 42.3 |
| CNLC staging, n (%) | |
| Ⅱa | 4 (7.3%) |
| Ⅱb | 9 (16.4%) |
| Ⅲa | 32 (58.2%) |
| Ⅲb | 10 (18.2%) |
| BCLC staging, n (%) | |
| B | 12 (21.8%) |
| C | 43 (78.2%) |
| Duration of lenvatinib (months), median (IQR) | 2.6 (1.6–3.3) |
| Cycles of camrelizumab, median (IQR) | 3 (2–4) |
| Number of TACE, median (IQR) | 1 (1–2) |
ECOG-PS, Eastern Cooperative Oncology Group performance status; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; PVTT, portal vein tumour thrombosis; CNLC, China liver cancer staging; BCLC, Barcelona Clinic liver cancer stage; TACE, transcatheter arterial chemoembolisation.